Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure

Nephrology Department,2 Hospital of IKA,Thessaloniki, Greece.
Hippokratia (Impact Factor: 0.37). 01/2011; 15(Suppl 1):22-6.
Source: PubMed

ABSTRACT In chronic kidney disease patients, bone and mineral abnormalities have a major impact on morbidity and mortality. Hyperphosphatemia has been associated with increased mortality and with the development of cardiovascular calcification, an independent predictor of mortality. Sevelamer, or more precisely 'sevelamer hydrochloride', is a weakly basic anion-exchange resin in the chloride form that was introduced in 1997 for the treatment of the hyperphosphataemia of patients with end-stage renal failure. Sevelamer sequesters phosphate within the gastrointestinal tract, so prevents its absorption and enhances its faecal excretion. Over the succeeding years, large numbers of patients have been treated with sevelamer, and it has fulfilled expectations in helping to control the hyperphosphataemia of end-stage renal failure. Additionally treatment with sevelamer was accompanied with lower incidence of hypercalcemia, decreased incidence of low PTH levels, a 15-31% decrease of LDL-cholesterol both in dialysis and predialysis patients, decreased C-reactive protein, amelioration of hyperuricemia and low fetuin A, decrease of uremic toxins, suggesting an overall anti-inflammatory effect. In incident dialysis patients, treatment with sevelamer has been associated with better survival, while in prevalent patients a clear benefit could only be demonstrated in older patients and in patients treated for more than 2 years. In dialysis patients, the treatment of hyperphospathemia with calcium based compounds, when compared with sevelamer, is associated with more frequent episodes of hypercalcemia, suppression of intact PTH and with progression of coronary calcifications. In the presence of adynamic bone disease, calcium load has a significantly higher impact on aortic calcifications and stiffening. Sevelamer treatment resulted in no statistically significant changes in bone turnover or mineralization compared with calcium carbonate, but bone formation rate increased and trabecular architecture improved only with sevelamer. In conclusion, the treatment of hyperphosphatemia with sevelamer hydrochloride, a noncalcium and non-metal containing phosphate binder, is associated with a beneficial effect on vascular calcification progression, bone disease and most likely with a survival benefit in some hemodialysis patients populations. Sevelamer carbonate is an improved, buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphataemia in CKD patients. Sevelamer carbonate formulated as a powder for oral suspension presents a novel, patient- friendly alternative to tablet phosphate binders. Safety and efficacy of sevelamer carbonate powder compared with sevelamer hydrochloride tablets in CKD patients are equivalent, with Sevelamer carbonate having fewer side effects from gastrointestinal tract.

Download full-text


Available from: Sofia Spaia, Sep 29, 2015
1 Follower
44 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hyperphosphataemia is a known independent risk factor for cardiovascular mortality. The objective of the study was to compare the effects of two phosphate binders, sevelamer carbonate and calcium carbonate on endothelial function (EF) and inflammation in patients on peritoneal dialysis (PD) with Type 2 diabetes mellitus (T2DM). Fifteen subjects with hyperphosphataemia discontinued all phosphate binders to undergo a two-week washout and were assigned to sevelamer carbonate or calcium carbonate treatments for eight weeks. After a second two-week washout period, subjects crossed over to either of the alternate treatments for another eight weeks. At the beginning and end of each treatment, biomarkers of EF, pro-inflammatory cytokines, serum albumin, calcium, phosphate and lipids were measured. Sevelamer carbonate significantly improved lipid profile compared with calcium carbonate. Amongst the EF and pro-inflammatory biomarkers, sevelamer carbonate decreased serum endothelin-1, plasminogen activator inhibitor-1, C-reactive protein and interleukin-6. Both phosphate binders were effective in decreasing serum phosphate but sevelamer had a positive effect on EF. Treatment with sevelamer carbonate has beneficial effects compared with calcium carbonate in decreasing inflammation and improving EF in patients with T2DM on PD.
    Journal of Renal Care 04/2013; 39(2). DOI:10.1111/j.1755-6686.2013.12009.x
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The negative effect of chronic and excessive consumption of alcohol on bone metabolism is reported in the literature. The alcoholism causes a reduction in bone quality and delays fracture repair, among other deleterious effects. However, its effect on dental implants osseointegration is not fully established. The aim of this research was to investigate the influence of prolonged and excessive consumption of alcohol in osseointegration in rats. Thirty-five female 3 months aged rats were divided into five groups according to alcohol consumption period (control (no alcohol) and 3, 4, 5 and 6 months of alcohol consumption). All animals received solid food ad libitum. At 8 month of age, all animals received a dental implant in the right femur and euthanasia was performed one month after the implant placement (final n=27). Quantification of the percentage of bone-implant direct contact was performed by histomorphometry. Serum levels of calcium and phosphate were also measured. The groups that consumed alcohol during longer periods presented decreased percentages of bone-implant direct contact. The difference was higher in implants apical region. Alcohol consumption did not affect serum calcium levels, but raised the level of serum phosphate. Alcohol consumption increased caloric intake, but also increased weight loss. It was concluded that chronic and excessive consumption of alcohol can impair osseointegration in rats.
    Journal of Oral Implantology 01/2014; 41(3). DOI:10.1563/AAID-JOI-D-13-00111 · 1.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Secondary hyperparathyroidism (SHPT) is the major complication of Chronic Renal Failure (CRF) patients. Our study aimed to evaluate the effect of the calcium carbonate and alfacalcidol with hemodialysis (HD) on SHPT in CRF patients. Methods: Sixty CRF patients were collected from Center of Renal Diseases and Dialysis of Hodeidah, Yemen. They were diagnosed with SHPT and classified into three groups, the first group was treated by 1800 mg/day of calcium carbonate and 0.25 mcg /day of alfacalcidol with two HD sessions for 6 hours/week. The second group was treated by3600 mg /day of calcium carbonate and 1mcg /day of alfacalcidol with two HD sessions for 6 hours/week with. The third group was treated by 3600 mg /day of calcium carbonate and 1mcg /day of alfacalcidol with HD sessions for 12 hours/week. The biochemical assays of parathyroid hormone (PTH), serum calcium and serum phosphorous levels as indicators effect were carried out. Results: The results showed after administration of calcium carbonate and alfacalcidol with HD that the PTH, serum calcium and serum phosphorus levels to be significantly different between three groups (p < 0.05). On the other hand, we observed in the first group significant enhance in PTH and serum phosphorus levels (p < 0.05) while significant decrease (p < 0.05) in serum calcium level (p > 0.05).We also observed in the second group that the PTH and serum phosphorus levels were not affected while significant decrease (p < 0.05) in serum calcium level. However, the results of the third group showed that significant decrease (p < 0.05) in PTH level and non-significant reduce (p > 0.05) in serum phosphorus level while non-significant increase in serum calcium level (p > 0.05). Conclusion: The findings showed high quality of HD therapy (12 hr/ week) lead to reduce of PTH and serum phosphorus levels with increase of serum calcium level.
    International Journal of Pharmacy and Pharmaceutical Sciences 04/2014; 6(2):267- 272. · 1.59 Impact Factor